SDC1 and ovarian carcinoma: We recently reported that the human recombinant antibody, scFv OC-46F2, specific for the ectodomain of Syndecan-1, exerts an antitumor activity in vivo by reducing tumor growth and vascular maturation in experimental human melanoma and ovarian carcinoma murine models [22].